Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Intensively Timed Induction (ITI) Chemotherapy in Adults with Acute Myelogenous Leukemia (AML).

Michael Rytting, MD, Srdan Verstovsek, M.D., Ph.D., Guillermo Garcia-Manero, M.D., Farhad Ravandi-Kashani, M.D., Sherry Pierce, R.N., Elihu Estey, M.D.

Blood (2007) 110 (11): 1851.

https://doi.org/10.1182/blood.V110.11.1851.1851

Published: 2007

Journal Articles

Pegylated Interferon-alfa-2a (PEG-IFN-α-2A; PEGASYS™) for Essential Thrombocythemia (ET) and Polycythemia Vera (PV): An Update of an Ongoing Phase II Study.

Alfonso Quintás-Cardama, MD, Hagop Kantarjian, M.D., Guillermo Garcia-Manero, M.D., Jorge Cortes, M.D., Marie Ann Richie, Gautam Borthakur, M.D., Srdan Verstovsek, M.D., Ph.D.

Blood (2007) 110 (11): 3542.

https://doi.org/10.1182/blood.V110.11.3542.3542

Published: 2007

Journal Articles

Phase II Study of Lenalidomide and Prednisone for Patients with Myelofibrosis.

Alfonso Quintás-Cardama, MD, Ayalew Tefferi, M.D., Deborah Thomas, M.D., Jorge Cortes, M.D., Farhad Ravandi, M.D., Stefan Faderl, M.D., Guillermo Garcia-Manero, M.D., Gautam Borthakur, M.D., Neda Bell, M.D., Catriona Byrne, M.D., Hagop Kantarjian, M.D., Srdan Verstovsek, M.D., Ph.D

Blood (2007) 110 (11): 3545.

https://doi.org/10.1182/blood.V110.11.3545.3545

Published: 2007

Journal Articles

Survival Benefit with Decitabine Compared to Historical Experience with Intensive Chemotherapy in Patients with Higher Risk Myelodysplastic Syndrome (MDS).

Elias Jabbour, MD, Hagop M. Kantarjian, M.D., Jorge Cortes, M.D., William G. Wierda, M.D., Ph.D., Alessandra Ferrajoli, M.D., Stefan Faderl, M.D., Susan O’Brien, M.D., Farhad Ravandi-Kashani, M.D., Srdan Verstovsek, M.D., Ph.D., Guillermo Garcia-Manero, M.D., Jan Davisson, BS, ADN, Francis Giles, M.D., Jianqin Shan, Ph.D., Jean-Pierre Issa, M.D.

Blood (2006) 108 (11): 2652.

https://doi.org/10.1182/blood.V108.11.2652.2652

Published: 2006

Journal Articles

Phase II Study of Decitabine in Combination with Imatinib Mesylate in Patients with Accelerated (AP) or Blastic Phase (BP) of Chronic Myeloid Leukemia (CML).

Yasuhiro Oki, MD, Hagop M. Kantarjian, MD, Susan O’Brien, MD, Srdan Verstovsek, M.D, Ph.D, Vazaganush Gharibyan, Jorge Cortes, MD, Gail M. Morris, Guillermo Garcia-Manero, MD, Jean-Pierre Issa, MD

Blood (2005) 106 (11): 1099.

https://doi.org/10.1182/blood.V106.11.1099.1099

Published: 2005

Journal Articles

2 Chlorodeoxyadenosine (2-CdA) and Cytarabine (ara-C) Combination Is Effective and Safe in Idiopathic Hypereosinophilic Syndrome (HES).

Elias Jabbour, M.D., Srdan Verstovsek, M.D., Ph.D., Varsha Gandhi, Ph.D., M.S., B.S., Jorge Cortes, M.D., Francis Giles, M.D., Charles Koller, M.D., Susan O’Brien, M.D., William Plunkett, Ph.D., Guillermo Garcia-Manero, M.D., Ellen Jackson, Hagop Kantarjian, M.D., Michael Andreeff, M.D., Ph.D.

Blood (2004) 104 (11): 4764.

https://doi.org/10.1182/blood.V104.11.4764.4764

Published: 2004

Journal Articles

Clinical Significance of Molecular Monitoring in Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with Imatinib Therapy.

Jorge Cortes, M.D., Moshe Talpaz, M.D., Susan O’Brien, M.D., Dan Jones, M.D., Ph.D., Raja Luthra, Ph.D., Guillermo Garcia-Manero, M.D., Francis Giles, M.D., Jenny Shan, Ph.D., Srdan Verstovsek, M.D., Ph.D., Mary Beth Rios, R.N., Hagop Kantarjian, M.D.

Blood (2004) 104 (11): 272.

https://doi.org/10.1182/blood.V104.11.272.272

Published: 2004

Journal Articles

AMN107, Novel Aminopyrimidine Inhibitor of Bcr-Abl, Is Significantly More Potent Than Imatinib Mesylate Against Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Cells.

Mirna Golemovic, M.S., Miloslav Beran, M.D., Ph.D., Francis Giles, M.D., Taghi Manshouri, M.S.C., Deborah Thomas, M.D., Jorge Cortes, M.D., Paul Manley, M.D., Leila Alland, M.D., Patricia Rae, B.S.C., Margaret Dugan, M.D., Zeev Estrov, M.D., Ralph B. Arlinghaus, Ph.D., Hagop Kantarjian, M.D., Srdan Verstovsek, M.D., Ph.D.

Blood (2004) 104 (11): 2737.

https://doi.org/10.1182/blood.V104.11.2737.2737

Published: 2004

Journal Articles

Effects of Adaphostin, a Novel Tyrphostin Inhibitor, in Diverse Models of Imatinib Mesylate Resistance.

Joya Chandra, Ph.D., Jeannette Tracy, Mercedes Gorre, Ph.D., Moshe Talpaz, M.D., James Griffin, M.D., Srdan Verstovsek, M.D., Ph.D., Miloslav Beran, M.D., Charles Sawyers, M.D., Edward Sausville, M.D., Scott Kaufmann, M.D., Ph.D.

Blood (2004) 104 (11): 2097.

https://doi.org/10.1182/blood.V104.11.2097.2097

Published: 2004

Journal Articles

Organic Arsenic Lipid Derivatives Are More Potent and Less Toxic Than Inorganic Arsenic Trioxide in Preclinical Testing.

Xiaodong Cheng, M.D., Mirna Golemovic, M.S., Francis Giles, M.D., Ralph Zingaro, Ph.D., Ming-Zhang Gao, Ph.D., Emil J. Freireich, M.D., Michael Andreeff, M.D., Ph.D., Hagop M. Kantarjian, M.D., Srdan Verstovsek, M.D., Ph.D.

Blood (2004) 104 (11): 1803.

https://doi.org/10.1182/blood.V104.11.1803.1803

Published: 2004

Journal Articles

Intravenous Voriconazole (IV-VORI) Prevents Invasive Fungal Infections (IFI) in Patients (pts) with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS).

Gloria N. Mattiuzzi, M.D., Gladys Alvarado, M.D., Hagop M. Kantarjian, M.D., Srdan Verstovsek, M.D., Ph.D., Maria Cabanillas, M.D., Stefan Faderl, M.D., Joann T. Lim, PharmD, Francis Giles, M.D., Miloslav Beran, M.D., Ph.D, Susan O’Brien, M.D., Elihu H. Estey, M.D.

Blood (2004) 104 (11): 885.

https://doi.org/10.1182/blood.V104.11.885.885

Published: 2004

Journal Articles

PEG-Intron for Myeloproliferative Diseases: An Update of Ongoing Phase II Study.

Srdan Verstovsek, M.D., Ph.D., Kristie Lawhorn, BCLS, R.N., Francis Giles, M.D., Jorge Cortes, M.D., Deborah Thomas, M.D., Guillermo Garcia-Manero, M.D., Alessandra Ferrajoli, M.D., Stefan Faderl, M.D., Miloslav Beran, M.D., Ph.D., Moshe Talpaz, M.D., Hagop Kantarjian, M.D.

Blood (2004) 104 (11): 1517.

https://doi.org/10.1182/blood.V104.11.1517.1517

Published: 2004

NARROW

Intensively Timed Induction (ITI) Chemotherapy in Adults with Acute Myelogenous Leukemia (AML).

Pegylated Interferon-alfa-2a (PEG-IFN-α-2A; PEGASYS™) for Essential Thrombocythemia (ET) and Polycythemia Vera (PV): An Update of an Ongoing Phase II Study.

Phase II Study of Lenalidomide and Prednisone for Patients with Myelofibrosis.

Survival Benefit with Decitabine Compared to Historical Experience with Intensive Chemotherapy in Patients with Higher Risk Myelodysplastic Syndrome (MDS).

Phase II Study of Decitabine in Combination with Imatinib Mesylate in Patients with Accelerated (AP) or Blastic Phase (BP) of Chronic Myeloid Leukemia (CML).

2 Chlorodeoxyadenosine (2-CdA) and Cytarabine (ara-C) Combination Is Effective and Safe in Idiopathic Hypereosinophilic Syndrome (HES).

Clinical Significance of Molecular Monitoring in Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with Imatinib Therapy.

AMN107, Novel Aminopyrimidine Inhibitor of Bcr-Abl, Is Significantly More Potent Than Imatinib Mesylate Against Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Cells.

Effects of Adaphostin, a Novel Tyrphostin Inhibitor, in Diverse Models of Imatinib Mesylate Resistance.

Organic Arsenic Lipid Derivatives Are More Potent and Less Toxic Than Inorganic Arsenic Trioxide in Preclinical Testing.

Intravenous Voriconazole (IV-VORI) Prevents Invasive Fungal Infections (IFI) in Patients (pts) with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS).

PEG-Intron for Myeloproliferative Diseases: An Update of Ongoing Phase II Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only